Study study type PathologyT1T0Patientssample sizesROB Results

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtasine plus endocrine therapy
Harbeck (TDM1 plus ET), 2017
  NCT01817452
RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasine plus endocrine therapytrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible-/-NA
suggested
  • suggested 3.0-fold increase in pCR (PE)

es-BC - HR positive - (neo)adjuvant (NA) breast cancer - HR positive es-BC - HR positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtasine plus endocrine therapy
Harbeck (TDM1 plus ET), 2017
  NCT01817452
RCTes-BC - HER2 positive - (neo)adjuvant (NA), es-BC - HR positive - (neo)adjuvant (NA)trastuzumab emtasine plus endocrine therapytrastuzumab plus endocrine therapyWomen older than 18yr with histologically confirmed unilateral primary BC, no evidence of distant metastasis, ER and/or PR-positive and HER2-positive who were candidates for neoadjuvant chemotherapy were eligible-/-NA
suggested
  • suggested 3.0-fold increase in pCR (PE)